title: The future of iPS cells in advancing regenerative medicine.
abstract: Induced pluripotent stem (iPS) cells have great potential in regenerative medicine, including cell replacement therapies and disease modelling in vitro. However, with this potential comes several challenges, including clinical safety, reprogramming and differentiation efficiency, and compromised functionality of differentiated cell types after transplantation. Many of these issues arise from imprecise control of cell fate. With large-scale sequencing and genome-editing technologies we can now precisely manipulate the genome, which has expanded our knowledge of functional cell types and cell identity. These technologies may improve our efforts in generating iPS-derived therapeutic cells and in development of therapies for human diseases.
authors: The J. David Gladstone Institutes,University of California San Francisco,San Francisco,California 94158,USA.
authors: Peng
authors: P
authors: Liu
authors: The J. David Gladstone Institutes,University of California San Francisco,San Francisco,California 94158,USA.
authors: K E
authors: KE
authors: Li
authors: The J. David Gladstone Institutes,University of California San Francisco,San Francisco,California 94158,USA.
authors: Shaohua
authors: S
authors: Xu
mesh_terms: D000818:Animals; D064113:CRISPR-Cas Systems; D002454:Cell Differentiation; D059014:High-Throughput Nucleotide Sequencing; D006801:Humans; D057026:Induced Pluripotent Stem Cells / Q000502:physiology / Q000637:transplantation; D044968:Regenerative Medicine / Q000639:trends*